Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma.

BACKGROUND Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients. The frequency of such mutations in clinical cohorts and the presence of other actionable mutations in meningiomas are important to define. METHODS We used high-resolution array-comparative genomic hybridization to prospectively characterize copy-number changes in 150 meningiomas and then characterized these samples for mutations in AKT1, KLF4, NF2, PIK3CA, SMO, and TRAF7. RESULTS Similar to prior reports, we identified AKT1 and SMO mutations in a subset of non-NF2-mutant meningiomas (ie, ∼9% and ∼6%, respectively). Notably, we detected oncogenic mutations in PIK3CA in ∼7% of non-NF2-mutant meningiomas. AKT1, SMO, and PIK3CA mutations were mutually exclusive. AKT1, KLF4, and PIK3CA mutations often co-occurred with mutations in TRAF7. PIK3CA-mutant meningiomas showed limited chromosomal instability and were enriched in the skull base. CONCLUSION This work identifies PI3K signaling as an important target for precision medicine trials in meningioma patients.

[1]  P. Brastianos,et al.  ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma. , 2016, European journal of endocrinology.

[2]  M. Weller,et al.  Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. , 2016, Neuro-oncology.

[3]  D. Louis,et al.  Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy. , 2016, Journal of the National Cancer Institute.

[4]  R. Beroukhim,et al.  A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. , 2015, Neuro-oncology.

[5]  I. Mellinghoff,et al.  PI3K pathway inhibition in GBM—is there a signal? , 2015, Neuro-oncology.

[6]  W. Mason,et al.  Phase II study of PX-866 in recurrent glioblastoma. , 2012, Neuro-oncology.

[7]  Timothy C Ryken,et al.  Toward precision medicine in glioblastoma: the promise and the challenges. , 2015, Neuro-oncology.

[8]  R. Beroukhim,et al.  ARID1A and TERT promoter mutations in dedifferentiated meningioma. , 2015, Cancer genetics.

[9]  A. Órfão,et al.  Genetic/molecular alterations of meningiomas and the signaling pathways targeted , 2015, Oncotarget.

[10]  Robert T. Jones,et al.  Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia , 2015, Modern Pathology.

[11]  P. Wen,et al.  Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. , 2015, Neuro-oncology.

[12]  R. Hevner,et al.  Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas , 2014, The Journal of pathology.

[13]  R. Beroukhim,et al.  Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5 , 2014, Oncotarget.

[14]  P. Korkolopoulou,et al.  Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development , 2014, Virchows Archiv.

[15]  P. Wen,et al.  Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. , 2014, Neuro-oncology.

[16]  Alberto Orfao,et al.  Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. , 2014, Neuro-oncology.

[17]  P. Kober,et al.  EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas , 2014, Oncology letters.

[18]  Guy Jerusalem,et al.  Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy , 2014, Clinical Cancer Research.

[19]  John Y. K. Lee,et al.  Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.

[20]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[21]  Roland Eils,et al.  Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations , 2013, Acta Neuropathologica.

[22]  D. Eccles,et al.  Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas , 2013, Nature Genetics.

[23]  Robert T. Jones,et al.  Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations , 2013, Nature Genetics.

[24]  Christopher M. Jackson,et al.  Predictors of Visual Outcome Following Surgical Resection of Medial Sphenoid Wing Meningiomas , 2012, Journal of Neurological Surgery—Part B.

[25]  M. Loda,et al.  DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues , 2012, PloS one.

[26]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Razelle Kurzrock,et al.  PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.

[28]  Joseph Wiemels,et al.  Epidemiology and etiology of meningioma , 2010, Journal of Neuro-Oncology.

[29]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[30]  M. Samii,et al.  Medial Sphenoid Wing Meningiomas: Clinical Outcome and Recurrence Rate , 2006, Neurosurgery.

[31]  W. Poon,et al.  Rare mutation of PIK3CA in meningiomas , 2006, Acta Neuropathologica.

[32]  T. Gasser,et al.  Spheno-orbital meningiomas: interdisciplinary surgical approach, resectability and long-term results. , 2005, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[33]  S. Kropf,et al.  Different Activation of Mitogen-Activated Protein Kinase and Akt Signaling Is Associated with Aggressive Phenotype of Human Meningiomas , 2005, Clinical Cancer Research.

[34]  D. Lenartz,et al.  Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. , 1995, The American journal of pathology.

[35]  A. Hagemeijer,et al.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. , 1994, American journal of human genetics.

[36]  Olivier Delattre,et al.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas , 1994, Nature Genetics.

[37]  J. Haines,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.

[38]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.